NCT00433329已完成4 期
COMPASS 3: An Open-label, Multi-Center Study Employing a Targeted 6-Minute Walk Test (6-MWT) Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of Magnetic Resonance Imaging (MRI) on Cardiac Remodeling
Actelion0 个研究点目标入组 100 人开始时间: 2007年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 主要终点
- Number of Patients Reaching a 6-Minute Walk Test (6MWT) Distance ≥ 380 Meters
研究概览
简要总结
An open label, non-comparative study design is appropriate for this Phase 4 study designed to assess whether a core therapy of bosentan, either as monotherapy or with the addition of sildenafil, enables patients with pulmonary arterial hypertension (PAH) to achieve a 6-minute walk distance (6 MWD) of ≥380 meters after 28 weeks of therapy This design is also appropriate to pioneer the utility of cardiac MRI in assessing improved functional capacity in PAH and exploring its correlation with other parameters.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent prior to initiation of any study-mandated procedures.
- •Males or females ≥ 12 years of age (females of child-bearing potential must have been surgically sterilized or use a reliable method of contraception).
- •Symptomatic patients with the following types of PAH belonging to World Health Organization (WHO) Pulmonary Hypertension Classification Group I:
- •Idiopathic (IPAH)
- •Familial (FPAH)
- •Associated with PAH (APAH):
- •Collagen vascular disease
- •Drugs and toxins
- •Patients naïve to treatment with advanced PAH therapies (i.e., endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors or prostacyclins) with a right heart catheterization (RHC) showing all of the following:
- •Mean pulmonary arterial pressure (mPAP) ≥ 25 mm Hg
- •Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg or left ventricular end diastolic pressure (LVEDP) ≤ 15 mm Hg when PCWP is not accurately obtained
- •Pulmonary vascular resistance ≥ 3 Wood units
- •6-MWT distance ≥ 150 meters and < 360 meters.
排除标准
- •Patients with Pulmonary Hypertension (PH) belonging to WHO Classification Group II-V.
- •Patients with PAH (WHO PH Classification Group I) other than that listed in the Inclusion Criteria.
- •Pregnant and/or nursing.
- •Women of childbearing potential not using a reliable method of contraception.
- •Patients with known human immunodeficiency virus (HIV) infection.
- •Patients with significant vasoreactivity during right heart catheterization (i.e., a fall in mPAP to < 40 mm Hg with a decrease of ≥ 10 mm Hg and with a normal cardiac index ≥ 2.5 l/min.m^2).
- •Patients with restrictive lung disease (i.e., total lung capacity (TLC) < 60% of normal predicted value).
- •Patients with obstructive lung disease (i.e., forced expiratory volume/ forced vital capacity (FEV1/FVC) < 0.5).
- •Patients with impaired left ventricular function (LVEF <50%) or diastolic dysfunction.
- •Patients with portal hypertension, cirrhosis, moderate to severe liver impairment (Child-Pugh Class B or C), or liver enzymes (Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)) > 3.0 times the upper limit of normal range.
- •Treatment with glibenclamide (glyburide) and calcineurin inhibitors (cyclosporine A, tacrolimus) sirolimus, everolimus up to 1 week prior to Baseline (Day 1).
- •Patients currently receiving or predicted to require treatment, during the course of the study, with nitrates, protease inhibitors, or alpha-blockers.
- •Patients with a hemoglobin concentration < 75 % of the lower limit of the normal range or < 8.5 g/dL.
- •Patients currently receiving or predicted to require treatment with a prostanoid during the course of the study.
- •Patients with systolic blood pressure < 85 mm Hg.
- •Patients with body weight < 40 kg.
- •Patients who have received any investigational product within 90 days prior to Baseline.
- •Patients who previously received any advanced therapy for PAH (e.g., ERAs, PDE-5 inhibitors or prostacyclins).
- •Patients with hypersensitivity to sildenafil or any excipients of its formulation.
- •Patients with any contraindication to sildenafil treatment (i.e., nitrates).
- •Patients with any recent medical condition limiting the ability to comply with the study requirements (i.e., stroke, myocardial infarction).
- •Patients with unstable PAH whose disease state would prohibit the completion of study procedures, in the opinion of the investigator.
- •Patients unable to complete a MRI scan (e.g., claustrophobia).
- •Patients with permanent cardiac pacemakers, automatic internal cardioverter defibrillators (AICD's), neurostimulators, hearing aides, and other implanted metallic devices that are contraindicated during a MRI study.
- •Patients with conditions that would interfere with proper cardiac gating during MRI, such as atrial fibrillation or multiple premature ventricular contractions (PVCs)/premature atrial contractions (PACs).
- •Patients with conditions that prevent compliance with the protocol or the ability to adhere to therapy.
研究组 & 干预措施
Bosentan
Experimental
Oral bosentan 62.5 mg twice daily (BID) first 4 weeks, followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated, with the addition of sildenafil 20 mg thrice daily (TID) in patients who do not reach the 6-MWT distance threshold at Week 16
干预措施: Bosentan (Drug)
Bosentan
Experimental
Oral bosentan 62.5 mg twice daily (BID) first 4 weeks, followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated, with the addition of sildenafil 20 mg thrice daily (TID) in patients who do not reach the 6-MWT distance threshold at Week 16
干预措施: Sildenafil (Drug)
结局指标
主要结局
Number of Patients Reaching a 6-Minute Walk Test (6MWT) Distance ≥ 380 Meters
时间窗: at 16 weeks and at 28 weeks of a stepped approach to therapy
The 6MWT is a non encouraged test, which measures the walking distance covered over a 6 minute period
次要结局
未报告次要终点
研究者
相似试验
Unknown
不适用
Performance of OrbiSymm in Subjects Referred to Contra Lateral Breast SymmetrisationBreast Asymmetry Between Native Breast and Reconstructed BreastNCT02649283Orbix Medical Ltd.60
已完成
4 期
A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With AsthmaAsthmaNCT02233803GlaxoSmithKline239
已完成
不适用
Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or IfosfamideSoft Tissue SarcomaNCT01299506PharmaMar102
已完成
4 期
Study Comparing 17B Estradiol/TMG CC 1mg Vs. Tibolone In Postmenopausal WomenVasomotor SymptomsNCT00472004Wyeth is now a wholly owned subsidiary of Pfizer204
Unknown
3 期
Immunotherapy With Racotumomab in Advanced Lung CancerLung Cancer, Non-small CellNSCLCNCT01460472Recombio SL1,082